A cute migraine is defined as idiopathic, paroxysmal, recurring, moderate-to-severe attacks of unilateral, throbbing headache exacerbated by physical activity and accompanied by associated features such as anorexia, nausea, vomiting, photophobia, and phonophobia. 1 Prevalence rates of migraine vary geographically and range from 1.5% in Southeast Asia 2 to 14% in Western countries. [3] [4] [5] [6] [7] Furthermore, its occurrence is age (most common from ages 25-55 years), race, gender (three times more common in women than in men), and income dependent (affecting lower socioeconomic groups more). [3] [4] [5] [6] [7] Since migraine is a common illness, it imposes an enormous health burden on both patient and society. Work and productivity losses represent 80% to 89% of the economic burden of migraine. 8 While the mechanisms involved in the pathogenesis of migraine are still incompletely understood, it is thought that migraine is a disorder of cranial (pial and dural) blood vessels. 9 Alterations in the activity of 5-hydroxytryptamine (5-HT)-containing neurons in the raphe nuclei and/or norepinephrine-containing pathways originating from the locus coeruleus lead to depolarization of trigeminoperivascular sensory afferents and release of vasoactive neuropeptides (e.g., calcitonin gene-related peptide, neurokinin A, and substance P). This will result in vasodilation of pial and dural arteries (and arteriovenous shunts) and exacerbate nociceptive transmission leading to so-called sterile neurogenic inflammation. 10 Orthodromic conduction transmits this nociceptive impulse to the central nervous system (Figure 1 ), where it may induce associated symptoms accompanying migraine. Simultaneously, antidromic conduction along the trigeminovascular fibers spreads the depolarization to the neighboring tissues. 11 In addition, reflex activation of intrinsic cholinergic neurons from the facial nerve-which innervates predominantly extracranial blood vesselsamplifies trigeminovascular depolarization and hence the sterile neurogenic inflammation.
5-HT acts at a variety of 5-HT receptor types, and its wide range of pharmacological effects make its clinical use unacceptable. At least seven different 5-HT receptor subtypes (5-HT 1 through 5-HT 7 ) have been now identified. 12 Furthermore, the 5-HT 1 receptor family comprises five different receptors (5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 1E , and 5-HT 1F ) that couple to a G-protein to inhibit cyclic AMP formation. Immunohistological data suggest that 5-HT 1B receptors in the human trigeminovascular system predominate mainly in meningeal arteries, while 5-HT 1D receptors are found on trigeminal nerve endings. 13 Stimulation of 5-HT 1B receptors results in selective vasoconstriction of cranial vessels, whereas activation of 5-HT 1D receptors directly inhibits the release of proinflammatory neuropeptides.
14 Functional activity studies indicate that all 5-HT 1 agonists possess high affinity and relative specificity for 5-HT 1B , 5-HT 1D , and 5-HT 1F subtype receptors while having no appreciable affinity for 5-HT 2 , 5-HT 3 , or nonserotoninergic receptors. 15 The presence of 5-HT 1D receptors in the trigeminal nucleus caudalis, solitary tract nucleus, and dorsal horns of the C 1 and C 2 cervical spinal cord 16 might explain the dual central and peripheral neuromodulatory action of certain second-generation 5-HT 1B/1D agonists. [17] [18] [19] [20] [21] An overview of the in vitro receptor binding affinities and the EC 50 values for the constriction of cranial and coronary vessels is given in Table I .
OVERVIEW OF CURRENT AND EMERGING SECOND-GENERATION 5-HT 1B/1D AGONISTS
The pharmacokinetic properties and clinical efficacy of sumatriptan in the treatment of acute migraine are well established and have been extensively reviewed elsewhere. [22] [23] [24] [25] Despite its efficacy, its pharmacokinetic (low bioavailability, short plasma half-life, and low liposolubility) and pharmacodynamic shortcomings have prompted the pharmaceutical industry to develop more potent and selective 5-HT 1B/1D agonists. This review focuses on the in vitro and in vivo pharmacological properties and clinical efficacy of current and emerging second-generation 5-HT 1B/1D agonists. Three of them (naratriptan, rizatriptan, and zolmitriptan) are already marketed; eletriptan is in the prelaunch phase, while almotriptan and frovatriptan are still awaiting Food and Drug Administration and European Medi- cines Evaluation Agency (EMEA) approval. 26 The clinical development of a few others has been discontinued because of lack of advantage compared to sumatriptan (alniditan) or because of severe alteration in hepatic function (avitriptan). 27, 28 These agents will therefore not be included in our discussion. An overview of the pharmacokinetic properties and clinical efficacy of the second-generation 5-HT 1B/1D agonists is given in Tables  II and III, respectively. Evaluation of outcome measures of these secondgeneration 5-HT 1B/1D agonists is based on controlled clinical studies with at least 450 evaluable patients and conform to the guidelines set by the International Headache Society for trials of drugs in migraine. 29 In acute antimigraine trials, end points are assessed using standardized self-rating scales. At baseline and at 0.5, 1, 2, 3, and 4 hours after dosing, patients rate their headache severity using a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). A number of parameters can be derived from this scale: (1) pain relief (or reduction of headache severity from severe or moderate at baseline to mild or no headache 2 hours postdosing), (2) time to pain relief within 2 hours, and (3) time to complete abolition of headache. Pain relief, expressed as the number of patients improving from severe or moderate at baseline to mild or no headache 2 hours postdosing, is generally considered as a primary efficacy end point in acute migraine studies. This parameter will be used in this review to evaluate and compare the second-generation 5-HT 1B/1D agonists with sumatriptan and each other. Secondary measures of efficacy include functional disability (0 = normal; 1 = mildly impaired daily activities; 2 = severely impaired daily activities; 3 = unable to do activities, requires bed rest), the presence or absence of associated symptoms (nausea, vomiting, photophobia, and phonophobia) at the same time points as headache severity ratings, the use of a second study dose at 2 hours or additional analgesics/ antiemetics (rescue medication), absenteeism from work, and the incidence of headache recurrence within 24 hours of receiving study medication. Like data for sumatriptan, 24 data for 5-HT 1B/1D agonists-when available-reveal that efficacy is unaffected by gender, age, aura, or menses. 25, [30] [31] [32] Except for frovatriptan, which is a carbazole derivative, all second-generation 5-HT 1B/1D agonists discussed are 3,5-substituted tryptamine derivatives (Figure 2 ). In vitro experiments have revealed that some secondgeneration 5-HT 1B/1D agonists have higher potency for the 5-HT 1B and/or 5-HT 1D receptor than their parent compound, sumatriptan (Table I ). In addition to their strong vasoconstrictor effect in cranial arteries, all 5-HT 1B/1D agonists exhibit a small but significant constrictor response in human coronary arteries in vitro. 33 Furthermore, up to 15% of patients consistently report chest symptoms, including tightness, heaviness, pressure, and/or pain in the chest, neck, and/or throat. [34] [35] [36] Although noncardiac mechanisms have been invoked, serious cardiac events have been reported after administration of sumatriptan. 37 One study investigated human coronary artery contraction in vitro at therapeutic plasma concentrations and concluded that at therapeu- Therapeutic gain is defined as reduction of pain from severe or moderate to mild or none 2 hours postdosing. s.c., subcutaneous; i.n., intranasal; NR, not reported; S25, sumatriptan 25 mg; S50, sumatriptan 50 mg; S100, sumatriptan 100 mg. a. At 4 hours postdose.
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tic doses, 5-HT 1B/1D agonists are unlikely to cause myocardial ischemia in individuals with normal coronary circulation. 33 Similarly, a positron emission tomographic study revealed that sumatriptan at therapeutic plasma concentrations does not affect myocardial perfusion in healthy female migraineurs. 38 Despite this, in patients with preexisting coronary artery lesions or Prinzmetal's angina, even a minor contraction of coronary arteries that might occur at therapeutic plasma concentrations of 5-HT 1B/1D agonists could potentially have deleterious effects, resulting in myocardial ischemia. Placebo-controlled studies have reported chest-related adverse effects in up to 4% of patients treated with second-generation 5-HT 1B/1D agonists compared to < 1% to 3% in placebo recipients. [39] [40] [41] [42] [43] Assuming that these agents have cardiovascular risk profiles similar to that of their parent compound sumatriptan, all 5-HT 1B/1D agonists should therefore be used with caution in any patient with vascular risk factors and avoided in those with concomitant uncontrolled hypertension, preexisting coronary heart disease (angina pectoris, asymptomatic episodes of ischemia documented by electrocardiography, history of myocardial infarction), or those with Prinzmetal's angina or cerebrovascular and peripheral vascular disorders. 37 Other side effects shared by these 5-HT 1B/1D agonists are fatigue, dry mouth, nausea, dizziness, somnolence, paresthesia, warm sensation, and flushing. 23, 24, 28, 37 The pharmacokinetics of sumatriptan is not affected by alcohol or by concomitant administration of any of the following drugs: dihydroergotamine, propranolol, flunarizine, pizotyline, naratriptan, or paroxetine. 22, 24 Because the combination of ergot-containing drugs and 5-HT 1B/1D agonists may theoretically result in prolonged vasospastic reactions, their concurrent use should be avoided. Similarly, it is not advised to combine two 5-HT 1B/1D agonists with each other. Selective 5-HT reuptake inhibitors have been reported, rarely, to cause serotonin syndrome when coadministered with sumatriptan. 24 However, to date, no reports of serotonin syndrome have been published due to the concurrent use of selective 5-HT reuptake inhibitors with second- Table IV . These data should be considered as preliminary because drug interaction data for some of the second-generation 5-HT 1B/1D agonists (e.g., almotriptan, frovatrip-tan) are still scanty.
Almotriptan
Hitherto, all data relating to almotriptan are available only in abstract form. Almotriptan shows selective and equipotent nanomolar affinity for 5-HT 1B and 5-HT 1D receptors. 44 Functional affinity assays indicate that almotriptan has a lower potency than sumatriptan at the 5-HT 1D receptor, while its potency at the 5-HT 1B receptor is similar to that of rizatriptan and sumatriptan. 44 Almotriptan, which is structurally related to sumatriptan, has a vasoconstrictor profile (25 times) superior to sumatriptan in human meningeal artery preparations. 44, 45 Oral and subcutaneous (s.c.) formulations have been developed. The oral formulation has the highest bioavailability among the second-generation 5-HT 1B/1D agonists; its half-life, however, is about 3.0 to 3.7 hours. 46 Almotriptan is metabolized via two primary routes: cytochrome P450 (CYP3A) is involved in the oxidation of the pyrrolidine moiety, and monoamine oxidase (MAO)-A catalyzes the oxidative deamination. 46 A large amount (45%) of the drug is found unchanged in the urine. 46 However, no dose adjustment is required in patients with mild to moderate renal impairment. 46 The MAO-A inhibitor (moclobemide) increases plasma concentrations of almotriptan by approximately 37%, but the combined administration of these compounds does not warrant dose adjustment. 47 The best efficacy/tolerability ratio is achieved with oral almotriptan 12.5 mg and s.c. 6 mg. 48, 49 At 2 hours, the response rate in patients receiving almotriptan 6 mg s.c. is 96.5% compared to 50% in placebo recipients. Besides transient local irritation effect at the injection site, no clinically relevant difference in frequency of systemic adverse events between treatments has been observed. Following oral almotriptan 12.5 mg, 60% of patients experience headache relief by 2 hours, compared with 64% and 42% for sumatriptan 100 mg and placebo recipients, respectively. 50 Almotriptan also has a favorable effect on secondary efficacy end points (e.g., migraine-associated symptoms, use of rescue medication, duration of migraine attack). Headache recurrence is lower (18%) in the almotriptan 12.5 mg group, compared to 25% and 20% in sumatriptan 100 mg and placebo group, respectively. Adverse events rates following 12.5 mg are clearly in favor of almotriptan and are not different from placebo (18% vs. 16% for placebo). Furthermore, almotriptan 12.5 mg has an advantageous tolerability profile compared to sumatriptan 100 mg. 50 Higher doses of almotriptan (25 mg) do not provide higher efficacy rates. Pharmacoeconomic studies are not yet available and are eagerly awaited.
Eletriptan
Eletriptan is a potent and selective partial agonist at the 5-HT 1B receptor and has one of the highest potencies of all second-generation 5-HT 1B/1D agonists at the human recombinant 5-HT 1D receptor, with faster association and slower dissociation rates than sumatriptan.
15,51 Both eletriptan and sumatriptan contracted human-isolated middle meningeal arteries more potently than the human coronary artery. 52 At therapeutic plasma concentrations, eletriptan's propensity to cause adverse coronary side effects is very limited. 53 Oral and intravenous formulations of eletriptan have been developed. The drug has an oral bioavailability of almost 50% and an elimination half-life ranging from about 4 to 7 hours. 54 An in vitro study in human hepatocytes showed that the metabolism of eletriptan is predominantly mediated by cytochrome P450 (CYP3A4). 55 Only 9% of the drug is found in the urine unchanged. During migraine attacks, its absorption may be delayed by up to 50%. 56, 57 In healthy volunteers, the combination of eletriptan and propranolol (80 mg bid for 7 days) leads to a slightly lower rate of elimination and a larger area under the plasma level-time curve (AUC) of eletriptan compared with eletriptan administered alone. 58 Dose-finding studies demonstrated the best ratio of efficacy and tolerability at an oral dose of 80 mg. 42, 59, 60 Two hours after dosing, eletriptan 80 mg reduced migraine headache in 65% to 80% of patients compared to 19% to 25% in the placebo group. 42, 61 In a comparative study, oral eletriptan was more effective in relieving headache than sumatriptan 50 mg (71% vs. 53%, respectively). 62 In addition, eletriptan proved to be superior to sumatriptan in onset of action and in achieving relief of migraine-associated symptoms. Last but not least, functional impairment by 2 hours was almost 15% lower in the eletriptan-treated patients compared to those receiving sumatriptan 50 mg. Headache recurrence following eletriptan varied between 21% and 33%. 61 The rate of adverse effects in patients randomized to eletriptan 80 mg (37%-51%) was comparable with that in the sumatriptan 100 mg group (40%-43%). Adverse events were generally transient and mild or moderate in intensity. Lower doses of eletriptan (e.g., 40 mg) reduced the incidence of treatment-related ad- 
Frovatriptan
Frovatriptan has one of the highest affinities for the human recombinant 5-HT 1B receptor of the secondgeneration 5-HT 1B/1D agonists. 15 Functional affinity assays indicate that frovatriptan exhibits vascularselective properties for human-isolated basilary arteries. 64 Frovatriptan has no effect on cardiac function or coronary hemodynamics after myocardial infarction and has an efficacy profile superior to that of sumatriptan. 65 Frovatriptan is rapidly absorbed from the duodenum and has an elimination half-life of up to 25 hours. 66 Renal clearance is the major route of elimination, with 50% of the dose excreted unchanged in the urine. Despite this, mild to moderate renal impairment does not necessitate dose adjustment. 66 There appears to be an age and gender difference, with plasma concentrations of frovatriptan being higher in elderly than young subjects and higher in females than males. 66 In healthy volunteers, pretreatment with propranolol (80 mg bid for 7 days) leads to a 25% increase in the bioavailability of frovatriptan compared with frovatriptan administered alone. 67 Dose-ranging studies have identified 2.5 mg of frovatriptan to be the optimal dose combining efficacy and tolerability for acute migraine. 43, 68 Despite its late stage of clinical development, results of published phase III studies are only available in abstract form. Across these studies, headache response rates for frovatriptan 2.5 mg at 2 hours ranged from 38% to 40% compared to 22% to 25% for placebo. At 4 hours, the respective figures were 66% to 68% and 33% to 35%. 68, 69 Headache recurrence rates after frovatriptan 2.5 mg ranged from 9% to 14% at 24 hours postdose, compared with 18% for placebo recipients. Incidence of adverse events at a dose of 2.5 mg was similar to placebo.
Naratriptan
Naratriptan exhibits a sixfold higher affinity for the human recombinant 5-HT 1B receptor than sumatriptan. 70 In addition, naratriptan has a vasoconstrictor profile superior to sumatriptan in human middle cerebral artery preparations. 70 Consequently, naratriptan had a higher vasoconstrictor activity compared to its parent molecule, sumatriptan. Both oral and s.c. formulations have been developed. The high oral bioavailability of naratriptan (almost 70%) in addition to its long half-life (about 5-7 hours) explains the low rate of headache recurrence. 71 Subcutaneous naratriptan 5 mg, however, does not offer any advantage in clinical efficacy and tolerability over s.c. sumatriptan 6 mg, which has resulted in the marketing of the oral formulation only. 72 Naratriptan has no active metabolites, and at therapeutic doses, no interactions have been reported with other antimigrainous agents. 73 Three large randomized double-blind, placebocontrolled, multicenter trials demonstrated that the 2.5 mg dose offers the best ratio of efficacy and tolerability. 41, 74, 75 The results of these studies revealed that 60% to 68% of patients taking 2.5 mg naratriptan and 33% to 34% of placebo recipients had headache relief at 4 hours. Furthermore, maintenance of headache relief (up to 24 hours postdose with no use of rescue medication) was observed in 43% to 52% of patients receiving naratriptan 2.5 mg compared with 19% to 22% of patients receiving placebo. 41, 74 Although not included in the original paper by Mathew et al, 41 2-hour response rate for naratriptan 2.5 mg was 49% compared with 27% for placebo. O'Quinn et al 76 evaluated the efficacy of naratriptan 2.5 mg and compared it with that of sumatriptan 100 mg. At 2 hours postdose, on average, 54% of naratriptan-treated patients experienced headache relief compared with 60% and 33% of sumatriptan-treated patients and placebo recipients, respectively. 76 The tolerability profile of naratriptan was comparable to placebo in these clinical trials. At a dose of naratriptan 2.5 mg, headache recurrence rate 24 hours postdose was low (17% to 28%) compared with 36% to 44% and 10% to 38% for sumatriptan and placebo recipients, respectively. One comparator trial evaluated the clinical efficacy and tolerability of naratriptan and rizatriptan and will be reported in the section on rizatriptan. Recently, a study evaluating the 24-hour efficacy and tolerability of naratriptan 2.5 mg with that of zolmitriptan 2.5 mg was unfortunately discontinued because of logistical issues. 77 Following repeated administration for multiple attacks of migraine over a 6-month period, the efficacy of naratriptan 2.5 mg was maintained, with no tachyphylaxis. 78 In this study, headache relief 4 hours postdose was reported in 68% of 6770 moderate or severe migraine attacks, with only 13% of attacks requiring a second naratriptan tablet due to headache recurrence. Furthermore, in only 17% of attacks, naratriptan treatment was associated with adverse events, which were mild and transient in nature. In a clinical setting, s.c.-administered naratriptan caused a vasopressor response in the systemic and pulmonary arterial circulation but did not induce coronary artery vasoconstriction. 79 Pharmacoeconomic studies showed the superiority of naratriptan over customary therapy on migraine patients' healthrelated quality of life.
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Rizatriptan
Radioligand displacement studies showed that rizatriptan has a lower affinity at both the 5-HT 1B and 5-HT 1D receptors compared to sumatriptan. 17 However, in vitro functional assays revealed that rizatriptan is as potent as almotriptan and sumatriptan at the human recombinant 5-HT 1B receptor and exhibits a higher potency than sumatriptan at the 5-HT 1D receptor. 15 Compared to sumatriptan, rizatriptan has 10-fold less vasoconstrictor activity in human-isolated coronary arteries than in the middle meningeal artery, confirming its vascular-selective properties. 12 Rizatriptan is available as oral formulation (5 and 10 mg) plain tablets and as a rapidly disintegrating wafer. The wafer is a freeze-dried dosage formulation that disintegrates on the tongue, is swallowed with saliva, and may be taken without liquids. Rizatriptan is well absorbed after oral administration and demonstrates bioavailability of approximately 45% with extensive first-pass metabolism via oxidative deamination. 81, 82 Only 14% of the unchanged drug is eliminated in the urine. Its half-life in plasma is approximately 2 to 3 hours. 81, 83 No dose adjustment is required in the elderly or in patients with hepatic or renal impairment. In view of its metabolic pathway, rizatriptan should not be administered concomitantly with MAO-A inhibitors. 84 In contrast to metoprolol and nadolol, propranolol increases rizatriptan plasma levels by 70%; therefore, dose reduction should be advised in patients taking rizatriptan and propranolol concomitantly. 31 No interaction has been reported between rizatriptan and the selective 5-HT reuptake inhibitor, paroxetine. 85 Large randomized, double-blind, placebo-controlled studies indicated that oral rizatriptan 10 mg provides the optimal balance between efficacy and tolerability. 39, [86] [87] [88] [89] [90] In these studies, 48% to 77% of rizatriptan patients had pain relief at 2 hours, compared with 18% to 40% of placebo recipients. Rizatriptan 10 mg was also very effective in reducing migraine-associated symptoms at 2 hours (38% vs. 61% in placebo group). 90 Three comparative double-blind trials of oral rizatriptan 10 mg and oral sumatriptan (50 or 100 mg) revealed similar efficacy profiles for headache relief 2 hours postdose (52%-72% vs. 46%-68%, respectively). 39, 88, 89 However, rizatriptan was superior to sumatriptan with regard to time to headache relief, number of patients being pain free at 2 hours postdose, and migraine-associated symptoms. Furthermore, its beneficial effect was maintained when used to treat multiple migraine attacks. 87 Also, 24-hour headache recurrence rates were almost similar in the rizatriptan group (35%-47%) compared to 20% to 59% and 31% to 41% in the placebo and sumatriptan groups, respectively. Across these clinical studies, adverse events during rizatriptan treatment were typical for drugs of this class. Quality-of-life studies indicated that rizatriptan 10 mg was superior to sumatriptan 50 mg and clearly resulted in less functional disability. 91 Furthermore, rizatriptan proved to be superior to customary therapy with regard to absenteeism, effectiveness at work, and difficulty with work-related tasks. 92 Two large randomized, double-blind, placebo-controlled trials compared the efficacy and tolerability of rizatriptan 10 mg with other second-generation 5-HT 1B/1D agonists. The first study compared rizatriptan 10 mg with naratriptan 2.5 mg. 93 At 2 hours, headache relief was obtained in 69% of patients randomized to rizatriptan, compared to 48% of patients receiving naratriptan. No headache response rates were reported 4 hours postdosing, which could have tilted the balance in favor of naratriptan. Rizatriptan proved also to be superior on secondary end points (time to onset of headache relief, time to relief of associated migraine symptoms, and number of patients with normal functioning 2 hours postdose). The second study compared the clinical efficacy and tolerability of rizatriptan 10 mg with zolmitriptan 2.5 mg. 94 Significantly more patients were pain free at 2 hours on rizatriptan than on zolmitriptan (43% vs. 36%). Rizatriptan also provided earlier painfree response within 2 hours, more effective relief in associated symptoms, and faster returning to normal functioning. In both studies, the tolerability profiles of the drugs were comparable. Headache recurrence rates, however, were not reported in these studies.
Zolmitriptan
Zolmitriptan is a partial agonist at the vascular 5-HT 1B/1D receptor. Radioligand displacement studies showed that zolmitriptan has a high affinity at both the 5-HT 1B and 5-HT 1D receptors. 17 Zolmitriptan is available as oral formulation, but intranasal and fast-melt oral formulations are in clinical development. Its oral bioavailability is almost 50%, and its half-life is comparable to that of rizatriptan (1.5-3.6 h). 95 One unique pharmacokinetic "fingerprint" is its large volume of distribution, which probably contributes to its dual peripheral and central mode of action. Primary metabo-lism of zolmitriptan is dependent mainly on CYP1A2, whereas MAO-A is responsible for further metabolism of the active metabolite (N-desmethyl-zolmitriptan). 96 The latter appears to be two to six times more potent at the 5-HT 1D receptor and is therefore very likely to contribute to the therapeutic activity of zolmitriptan. Age, renal impairment, and moderate hepatic impairment do not affect plasma pharmacokinetics significantly and hence do not require dose adjustment. 95 No clinically significant interactions with the following antimigrainous drugs have been reported: dihydroergotamine, ergotamine, pizotifen, fluoxetine, and acetaminophen/metoclopramide. 97, 98 Coadministration of propranolol resulted in a 56% increase in the AUC of zolmitriptan, 98 but with no significant effect on cardiovascular response. 98 Since the MAO-A inhibitor, moclobemide, has the potential to decrease the clearance of N-desmethyl-zolmitriptan, it may be advised to reduce the dose of zolmitriptan in those migraine patients taking zolmitriptan and moclobemide concomitantly. 97 Cimetidine increased both the half-life and AUC of zolmitriptan. In addition, the half-life and AUC of its active metabolite were doubled. Based on this, potential interactions with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) can theoretically be expected.
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Several large, randomized, placebo-controlled trials have shown the optimal ratio of efficacy and tolerability at the oral dose of 2.5 mg. [100] [101] [102] [103] [104] At this dose, headache relief was achieved at 2 hours in 62% to 65% of patients compared with 19% to 36% of those given placebo. By 4 hours, 70% to 78% of zolmitriptantreated patients achieved headache relief compared with 36% to 37% in the placebo group. Similar efficacy (67%) was achieved with zolmitriptan 5 mg. 101, 103 Zolmitriptan was also effective in treating recurrent or persistent headache following first-dose failure. Headache recurred within 24 hours in 21% to 37% of patients treated with zolmitriptan compared to 30% to 65% in the placebo group. Doses of zolmitriptan (5 mg) proved consistently effective for treatment of multiple attacks for up to 1 year, with no tachyphylaxis. 32, 105 Data comparing efficacy and tolerability between zolmitriptan and sumatriptan are available from one trial, but methodological flaws make the interpretation difficult. 106 One randomized, double-blind, placebocontrolled study compared the clinical efficacy and tolerability of zolmitriptan with that of rizatriptan. The results of this trial were reported in the section on rizatriptan. Across all clinical trials, adverse events were generally mild or moderate in intensity, brief in duration, and similar in nature to those observed with sumatriptan.
CONCLUSIONS
Inhibition of neurogenic inflammation and restoration of central inhibition provide a rationale for using 5-HT 1B/1D agonists in the acute treatment of migraine. The successful introduction of sumatriptan has led to an upsurge of second-generation 5-HT 1B/1D agonists with increased potency and selectivity at the 5-HT 1B/1D receptor, improved pharmacokinetic, and/or clinical properties. Almotriptan has a low headache recurrence rate and shows an improved tolerability profile. However, more comparative trials versus sumatriptan and other second-generation 5-HT 1B/1D agonists are awaited to determine its place in the treatment of acute migraine. The clinical efficacy of eletriptan is one of the highest among the oral second-generation 5-HT 1B/1D agonists; however, its downside might be its slightly higher incidence of treatment-related adverse events. Although data for frovatriptan are scanty, the drug appears to be one of the most promising agents. Its very long half-life translates to the lowest rate of headache recurrence reported for second-generation 5-HT 1B/1D agonists. Furthermore, it has been shown to have a low incidence of adverse events. Naratriptan offers a slightly higher efficacy profile compared to sumatriptan. Furthermore, the headache recurrence rate following naratriptan is among the lowest reported with the newer second-generation 5-HT 1B/1D agonists. The wafer formulation of rizatriptan offers a convenient benefit for the treatment of migraine headache. Rizatriptan has a faster onset of action than oral sumatriptan and makes more patients headache free with significantly less migraine-associated symptoms. Zolmitriptan is one of the best-documented secondgeneration 5-HT 1B/1D agonists. The drug is rapidly effective and well tolerated, which makes it a good alternative to sumatriptan. Pharmacoeconomic studies assessing the impact of these agents on health care budget seem to indicate that the higher cost of these 5-HT 1B/1D agonists may well be balanced by the overall reduction in cost of medical care. 107 Studies comparing clinical efficacy and cost will be needed to better determine the place of each of these second-generation 5-HT 1B/1D agonists in the treatment of acute migraine. Although differences among second-generation 5-HT 1B/1D agonists appear to be small, in our experience, clinical response and tolerability vary considerably among individual patients. Furthermore, up to 25% of patients do not respond to any of these agents. Whether this is due to pharmacodynamic reasons or an aberrant form of migraine remains unsolved but would justify development of other antimigraine agents such as tachykinin NK 1 receptor antagonists (e.g., lanepitant) or 5-HT 1F receptor agonists.
